Top Life Sciences and Healthcare GCC Heads in India 2026
Siva Kumar Padmanabhan
MD & Head of India Global Innovation & Technology Centre and VP, Global IT Enterprise Capabilities & Solutions, AstraZeneca India Private Limited
.webp)
Photo — AstraZeneca India Private Limited
Siva Kumar Padmanabhan is the Managing Director and Head of the India Global Innovation and Technology Centre at AstraZeneca India Private Limited (AZIPL).
He is also responsible globally for all Enterprise Capabilities and Solutions provided by AstraZeneca IT to the business. Since joining AstraZeneca in 2014, Siva has been playing a key role in the transformation of AZ-IT - right from insourcing IT services, building a strong leadership team, developing leading-edge data and digital capabilities and being a key enabler in expanding AZIPL's Indian footprint and innovation capability.
Siva is recognised among the Top 25 GCC Heads in India 2025 by Analytics India Magazine and was named one of India’s 100 Most Influential AI Leaders in 2024 for his commitment to enterprise innovation through AI. Siva is also a member of the NASSCOM GCC Council 2025-27.
Previously, Siva led the Global In-house Centre for IT & Digital at Flex, a Fortune 500 company, with global accountability for their customer-facing digital and supply chain solutions.
His earlier part of the career was in management and technology consulting with PwC, in India and the US. Siva has an MBA in Finance and Information Systems from the Indian Institute of Management (IIM), Bangalore.
Join the conversation
Discussion
More honorees
From Top Life Sciences and Healthcare GCC Heads in India 2026

John Dawber
Vice President & Managing Director - Global Business Services · Novo Nordisk

Kalavathi G V
Executive Director and Head, Global Development Center · Siemens Healthineers
.webp)
Mohit Dhingra
Managing Director, Hyderabad and Vice President and Head of Business Insights & Technology, Hyderabad · Bristol Myers Squibb
.webp)
Mrinal Duggal
Head of Sanofi Hyderabad Hub · Sanofi
.webp)
.webp)
What's your take on this story?
No comments yet — be the first to share your view.